# A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Study · id `cardio:ct-nct01760447` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01760447](<https://clinicaltrials.gov/study/NCT01760447>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01760447

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 223 participants.

## Technical summary

Registry record NCT01760447. Randomized; quadruple masking; primary purpose treatment. Start 2011-12-07 (actual); primary completion 2019-09-17 (actual). Results posted on 2020-10-05.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 223 participants (enrolled count; ClinicalTrials.gov record NCT01760447, source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)
- Started: 2011-12-07 (actual) (ClinicalTrials.gov record NCT01760447, source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)
- Primary completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT01760447, source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)
- Completion: 2019-09-17 (actual) (ClinicalTrials.gov record NCT01760447, source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)
- Results first posted: 2020-10-05 (ClinicalTrials.gov record NCT01760447, source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01760447-2022-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sitagliptin plus metformin
- Intervention (Drug): Placebo to metformin
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo to sitagliptin plus metformin
- Intervention (Drug): Sitagliptin plus metformin XR
- Intervention (Drug): Placebo to metformin XR
- Intervention (Drug): Insulin
- Intervention (Drug): Placebo to sitagliptin plus metformin XR
- Intervention (Drug): Metformin XR
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 4b98cb54a11977266cfb06f0e57899d549bb1a3a9b5bf72efbd4e6c5e46d0324
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
